Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT02438501
Other study ID # WuhanU
Secondary ID
Status Recruiting
Phase Phase 3
First received April 27, 2015
Last updated December 11, 2015
Start date October 2015
Est. completion date October 2025

Study information

Verified date December 2015
Source Wuhan University
Contact Di Deng, MD
Phone 0086-27-67813153
Email dengdi69@163.com
Is FDA regulated No
Health authority China: Ethics Committee
Study type Interventional

Clinical Trial Summary

Many trials that patients with advanced or recurrent indolent lymphoma managed with very low-dose (4Gy) limited-field RT (LD-IFRT) have shown that high response rates and durable remission can be achieved. However, the results of two phase III trials have failed to demonstrate the lasting response rate (RR) with LD-IFRT versus in other approaches. Histology, bulky tumor (>5 cm), higher number of prior chemotherapy regimens, adoption of rituximab, and age>65 years have been shown to significantly influence response rates of LD-IFRT. The objectives of this trial investigate the efficacy of palliative low-dose involved-field radiation therapy in patients lower than 65 years of age with recurrent advanced follicular lymphoma.


Description:

Introduction: Follicular lymphoma(FL) often involves lymph nodes and the bone marrow and is widely regarded as a systemic and advanced-stage disease when it is diagnosed in more than two-thirds of patients at initial presentation. Follicular lymphoma Grade 1 or 2 with indolent histologic characteristics is presently not considered curable in the majority of patients though it is very sensitive to both chemotherapy and radiotherapy. The policy treated for patients with stage III and IV FL, which recommended by NCCN, is suggested regimens, clinical trial or local RT (palliation) based on the previous results that similar efficacy was obtained after management by chlorambucil single-agent therapy, polychemotherapy, immunochemotherapy, RT or CMT(RT and Chemotherapy). Patients with advanced-stage disease tend to have frequent relapses and the interval between subsequent relapses tends to shorten over time. However, they usually have a relatively long life expectancy, with a median survival ranging from 6 to 10 years. Try to change the natural history of FL and have a long term PFS are the goals of treatment for advanced stage FL.

Since the treatment strategy, watch and wait, was managed in Standford in the 1980s, several prospective randomized trials have failed to demonstrate a survival advantage with immediate treatment versus a "watch and wait" approach in patients with advanced stage, low tumor burden FL. Though many systemic therapy options are available for patients with stage III and IV FL, there is no consensus as to which first-line treatment should be provided to those patients. "Watch and wait" as a approach is still recommended to the patients even in the rituximab era. GELA provided the indications for treatment, when the treatment a patient should be initiated.

The role of traditional RT with or without chemotherapy in advanced stage FL is not definite. FL is considered to be one of the most radiosensitive tumors. However, a significant proportion of patients relapse with systemic disease outside of radiation fields and no difference in OS were observed in advanced patients between RT alone and CMT. The complications related to traditional RT, including cardiovascular disease and disorders of blood cell production, were needed to emphasize for those indolent advanced patients who need frequent palliative management and can long-term survive with NHL. In order to decrease the late complications after Large-field RT, reduction of irradiation field and smaller therapeutic doses of radiation were commonly managed.

Many trials that patients with advanced or recurrent FL managed with very low-dose (4Gy) limited-field RT have shown that high response rates and durable remission can be achieved. The response rates (either a complete or partial response) reported in previous study that low-dose involved-field RT (LD-IFRT) is given in 2 daily fractions (2×2 Gy) is 81% to 92%. The median time to first recurrence was 14 to 15 months. The median overall survival for patients with a positive response was 41 months. The median time to in-field progression was 21months, and the median time to out-field progression was 8 months. The predominant mode of tumor cell death after low-dose RT may be by apoptosis.

Two phase III trials have been designed to assess the further role of LD-IFRT. However, the results have failed to demonstrate the lasting response rate (RR) with LD-IFRT versus in other approaches. The HOVON 47/EORTC 20013 Intergroup study (www.hovon.nl) which compares LD-IFRT to chlorambucil chemotherapy in previously untreated FL patients, the main end points including progression-free survival and quality of life are evaluating. However, the trial was closed in 2005 after 21 cases included because of the clinical adoption of rituximab. The age of most eligible patients was older than 65 years. Another trial, Follicular Radiotherapy Trial (CRUK- FORT), launched recently in the United Kingdom is randomizing patients with FL needing RT to 24 Gy in 12 fractions versus 4 Gy in 2 fractions as either definitive or palliative treatment for FL. A significantly lower overall response rate (81% vs 74%) and 2-year local progression-free rate (94% vs 80%) were found in the 4Gy group. Over half of the patients in the clinic trial were on stage I and stage II. Moreover, the histologies included many other pathologic subtypes of indolent lymphoma besides follicular Grade 1 or 2.

The role of prognostic factors for treatment efficacy is not consensus. Histology has been shown to significantly influence response rates. Compared to other subtypes of indolent lymphoma, the higher response rate of low-dose involved-field radiotherapy (LD-IFRT) as palliative treatment for indolent lymphoma has been explored in follicular lymphoma.

Age at diagnosis, and prior systemic therapy are more estimated. In the retrospective review by Girinsky et al. 48 patients with indolent lymphoma treated with LD-IF-RT, factors that were significantly associated with lack of response including bulky tumor (>5 cm), higher number of prior chemotherapy regimens, and age>65 years. Haas et al. reported their experience of 109 patients with recurrent indolent B-cell NHL treated with LD-IF-RT. Patients with only one or two lymphoma sites and disease size of <5 cm were significantly more likely to achieve a CR.

The management for advanced FL patients with relapse disease after initial management can be affected by significant toxicity associated with Chemotherapy and Radiotherapy. The role of low-dose involved-field radiotherapy (LD-IFRT) as palliative treatment for advanced FL has been explored. LD-IFRT for selected patients including advanced FL, aged lower than 65 years and disease size of <5 cm may have excellent effection in achieving repeated remissions with limited associative toxicity and may postpone the need for systemic therapy. The management is valuable assessed.


Recruitment information / eligibility

Status Recruiting
Enrollment 166
Est. completion date October 2025
Est. primary completion date October 2019
Accepts healthy volunteers No
Gender Both
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria:

- Both male and female aged range from 18 years to 65 years.

- Eastern Cooperative Oncology Group(ECOG) performance status of 0 or 1.

- All patients had histological confirmed follicular lymphoma Grade 1 or 2.

- Recurrent patient with stage III and IV after initial management.

- Had the indications for treatment provided by GELA.

- Rituximab is too expensive to be managed for the patient.

- Adequate organ function.

- Negative pregnancy test.

- Signed informed consent document on file.

Exclusion Criteria:

- Woman who were pregnant or lactating.

- Had uncontrolled metastases in central nervous system.

- With severe local infection or general infective disease.

- Immunotherapy for the treatment of follicular lymphoma within 1 month prior to the start of this trial.

- With other second primary malignancy except cutaneum carcinoma.

- Being or planing to participate in other study.

- Any patient who in the opinion of the investigator should not participate in the study.

Withdrawal Criteria:

- Patient are free to withdrawal completely from the study at any time upon request.

- Patient in the study may be stopped with the patient agreement at any time at the discretion of investigator.

- Continual consolidation chemotherapy after irradiation within the follow-up period.

- In-field progression on irradiation ongoing.

- Poor tolerability adverse events in the period of chemotherapy or irradiation after enrolled in the study.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment


Intervention

Radiation:
Low-dose involved-field radiotherapy
Low-dose involved-field RT (LD-IFRT) is given in 2 daily fractions (2×2 Gy). Involved-field of radiotherapy defined by CALGB is encompassed the prechemotherapy gross tumor.
Involved-field radiotherapy
Involved-field RT (IFRT) is given in 24 Gy in 12 fractions. Radiotherapy field defined by CALGB is encompassed the prechemotherapy gross tumor.

Locations

Country Name City State
China DiDeng Wuhan Hubei

Sponsors (1)

Lead Sponsor Collaborator
Di Deng

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Overall response rates - ORR At day 30 after radiotherapy No
Primary Time to treatment failure - TTF From the start of radiotherapy to the first documented disease progression or death from any cause, whichever occurs first, Assessed up to 40 months. No
Primary Number of participants with adverse events with grade 3 or 4 - AEs Toxicity was scored according to the toxicity scale of the National Cancer Institute Common Terminology Criteria for Adverse Events 3.0. The time from the day of treatment to the day of the first documented disease progression or death from any cause, Assessed up to 24 months. No
Secondary Overall survival - OS From the initial diagnosis of follicular lymphoma to death from any cause, Assessed up to 100 months. No
Secondary Rate of in-field progression From the start of RT to the first documented disease progression within the radiotherapy portal, Assessed up to 24 months. No
Secondary Rate of out-field progression From the start of RT to the first documented disease progression outside the radiotherapy field, Assessed up to 40 months. No
See also
  Status Clinical Trial Phase
Withdrawn NCT04635683 - Lenalidomide, Umbralisib, and Ublituximab for the Treatment of Relapsed or Refractory Indolent Non-Hodgkin Lymphoma or Mantle Cell Lymphoma Phase 1
Active, not recruiting NCT02153580 - Cellular Immunotherapy Following Chemotherapy in Treating Patients With Recurrent Non-Hodgkin Lymphomas, Chronic Lymphocytic Leukemia, or B-Cell Prolymphocytic Leukemia Phase 1
Active, not recruiting NCT01955499 - Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma Phase 1
Recruiting NCT04007029 - Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or Refractory B-Cell Lymphoma or Chronic Lymphocytic Leukemia Phase 1
Withdrawn NCT03579927 - CAR.CD19-CD28-zeta-2A-iCasp9-IL15-Transduced Cord Blood NK Cells, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Participants With B-cell Lymphoma Phase 1/Phase 2
Active, not recruiting NCT04578600 - CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell Lymphoma Phase 1
Recruiting NCT04447716 - An Early Phase Study of Venetoclax, Lenalidomide, and Rituximab/Hyaluronidase in Slow-Growing Lymphomas That Have Come Back After Treatment or Have Not Responded to Treatment Phase 1
Completed NCT03019640 - Umbilical Cord Blood NK Cells, Rituximab, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Patients With Recurrent or Refractory B-Cell Non-Hodgkin's Lymphoma Phase 2
Completed NCT02927964 - TLR9 Agonist SD-101, Ibrutinib, and Radiation Therapy in Treating Patients With Relapsed or Refractory Grade 1-3A Follicular Lymphoma Phase 1/Phase 2
Completed NCT02869633 - Ibrutinib in Treating Patients With Refractory or Relapsed Lymphoma After Donor Stem Cell Transplant Phase 2
Completed NCT01995669 - Lenalidomide and Obinutuzumab in Treating Patients With Relapsed Indolent Non-Hodgkin Lymphoma Phase 1/Phase 2
Terminated NCT01028716 - Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies Phase 2
Withdrawn NCT05152459 - Tazemetostat in Combination With Umbralisib and Ublituximab for the Treatment Relapsed or Refractory Follicular Lymphoma Phase 1/Phase 2
Terminated NCT04156828 - Copanlisib and Combination Chemotherapy for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma or Relapsed Grade 3b Follicular Lymphoma Phase 1
Active, not recruiting NCT03035331 - Dendritic Cell Therapy, Cryosurgery, and Pembrolizumab in Treating Patients With Non-Hodgkin Lymphoma Phase 1/Phase 2
Active, not recruiting NCT03401853 - Pembrolizumab With Rituximab or Obinutuzumab in Treating Patients With Relapsed or Refractory Follicular Lymphoma or Diffuse Large B Cell Lymphoma Phase 2
Active, not recruiting NCT03479268 - Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory CLL or Non-Hodgkin Lymphoma Phase 1
Recruiting NCT02721407 - Anti-CD22 CAR-T Therapy for CD19-refractory or Resistant Lymphoma Patients Phase 1
Recruiting NCT06191887 - B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide Lymphodepletion for the Treatment of Relapsed or Refractory B-cell Hematologic Malignancies Phase 1
Active, not recruiting NCT04205409 - Nivolumab for Relapsed, Refractory, or Detectable Disease Post Chimeric Antigen Receptor T-cell Treatment in Patients With Hematologic Malignancies Phase 2